Stocks / TECH
TECH stock forecast
BIO-TECHNE CORP · Healthcare · Biotechnology
The model's rating
Greatly Underperform
TECH is rated Greatly Underperform as of September 29, 2026: its medium-term return forecast is in the bottom fifth of the stocks the model scores.
Create a free account to compare any two stocks; the numeric score is part of Premium.
TECH is not among the 20 largest holdings published for 2026 Q4. See the portfolio
TECH against the S&P 500
| Period | TECH | S&P 500 (SPY) |
|---|---|---|
| 1 month | +0.2% | -0.3% |
| 3 months | +2.3% | +2.5% |
| Year to date | +23.9% | +12.7% |
| 1 year | +31.1% | +15.7% |
Total return, dividends included.
Key numbers
| Price | $72.47 |
| Market cap | 11.36 Billion |
| P/E (trailing 12 months) | 61.9 |
| P/S (trailing 12 months) | 9.3 |
| P/B (latest quarter) | 5.4 |
| Gross margin | 65.8% |
| Net profit margin | 15.0% |
| Return on equity | 8.9% |
| Beta | 0.8 |
As of August 24, 2026.
TECH and its closest peers
| Stock | Company | Market cap | Model rating | |
|---|---|---|---|---|
| INCY | INCYTE CORP | 24.6 Billion | Greatly Outperform | INCY vs TECH |
| MRNA | MODERNA INC | 76.88 Billion | Greatly Underperform | MRNA vs TECH |
| REGN | REGENERON PHARMACEUTICALS INC | 78.07 Billion | Greatly Outperform | REGN vs TECH |
| VRTX | VERTEX PHARMACEUTICALS INC | 132.51 Billion | Outperform |
Questions
What does the Upfront Investment model say about TECH?
The model rates BIO-TECHNE CORP (TECH) "Greatly Underperform" as of September 29, 2026, which means its medium-term return forecast is in the bottom fifth of the stocks the model scores. The rating is a statistical forecast, not a recommendation to buy or sell.
How is the TECH rating produced?
A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.
Is TECH in the Upfront Investment model portfolio?
TECH is not among the 20 largest holdings published for 2026 Q4.
The rating is the output of a statistical model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.